Product information and disease descriptionProduct descriptionProduct information
Indication
5 evidence topics · 9 sources
Population of the pivotal AMPLITUDE trial: primary AMKD with severe proteinuria and no kidney disease-causing comorbidities
Indication named for a potential accelerated approval: patients with AMKD
Age range in AMPLITUDE: 10 to 65 years
Indications named in regulatory designations: APOL1-mediated FSGS (FDA) and AMKD (EMA)
| Field | Quoted record |
|---|---|
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |